MedPath

Insulin Glargine During and After the Period of Fasting in Ramadan

Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
Registration Number
NCT00258804
Lead Sponsor
Sanofi
Brief Summary

Primary Objectives :

* To compare the number of hypoglycaemic events (severe, symptomatic, asymptomatic, nocturnal) in patients with type 2 diabetes treated with insulin glargine (Lantus®) and glimepiride (Amaryl®), before, during and after the period of fasting in Ramadan.

Secondary Objectives :

* To assess glycaemic control before, during and after Ramadan in terms of HbA1c, FBG, and 8-point blood glucose profile (FBG and 8-point blood glucose profile will be collected with a blood glucose monitor through a monthly patient diary).

* To assess the relationship between hypoglycaemia events during Ramadan and blood glucose control prior and during Ramadan.

* To assess patient satisfaction

* To document adverse events (all serious adverse events, non serious adverse events) throughout the study (all events will be collected through the monthly patient diary).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
450
Inclusion Criteria
  • Patients with Type 2 Diabetes mellitus (but without history of ketoacidosis);

  • BMI > 25 and < 40 kg/m2;

  • Willingness to participate and to fast during Ramadan;

  • Patients should be either:

    • Insulin naïve patients
    • Patients already receiving insulin
Exclusion Criteria
  • Pregnancy (as determined by pregnancy blood test at inclusion visit)
  • Breast- feeding
  • Women of childbearing potential who do not have adequate contraceptive protection
  • Need for treatment during the study period with medications that may interfere with the study protocol
  • Treatment with any investigational drug (only if in trial) in the last 3 months before entry into the study
  • History of drug or alcohol abuse
  • Severe and unbalanced diabetic retinopathy
  • Clinically relevant cardiovascular, gastrointestinal, hepatic, renal, neurological, endocrine, hematological or other major systemic diseases that may interfere with the study protocol or complicate the interpretation of study results
  • Night shift workers

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Glycemic control before, during and after Ramadan in terms of HbA1c, FBG, 8-point blood glucose profile
All other adverse events before, during and after Ramadan
Patient satisfaction before, during and after Ramadan.
Hypoglycaemic events (severe, symptomatic, asymptomatic, nocturnal) before, during and after Ramadan
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath